Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis-Reference-Cited by-同舟云学术

Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis

Published:2022-01 Issue:1 Volume:20 Page:105-115.e14
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Sandborn William J.,Ferrante Marc^ORCID,Bhandari Bal R.,Berliba Elina,Hibi Toshifumi,D’Haens Geert R.,Tuttle Jay L.,Krueger Kathryn,Friedrich Stuart,Durante Michael,Arora Vipin,Naegeli April N.,Schmitz Jochen,Feagan Brian G.

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. Ulcerative colitis;Ordas;Lancet,2012

2. ACG clinical guideline: ulcerative colitis in adults;Rubin;Am J Gastroenterol,2019

3. Tofacitinib as induction and maintenance therapy for ulcerative colitis;Sandborn;N Engl J Med,2017

4. Vedolizumab as induction and maintenance therapy for ulcerative colitis;Feagan;N Engl J Med,2013

5. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis;Sandborn;Gastroenterology,2012

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies;Intestinal Research;2024-04-30

2. Model‐Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate‐to‐Severe Ulcerative Colitis;Clinical Pharmacology & Therapeutics;2024-04-16

3. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy;Frontiers in Immunology;2024-04-15

4. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study;Inflammatory Bowel Diseases;2024-03-09

5. Mirikizumab (Omvoh™) for ulcerative colitis;Trends in Pharmacological Sciences;2024-03